Literature DB >> 6087322

Identification of Epstein-Barr virus sequences that encode a nuclear antigen expressed in latently infected lymphocytes.

J C Hearing, J C Nicolas, A J Levine.   

Abstract

The Epstein-Barr virus (EBV) BamHI restriction endonuclease fragment K (B95-8 strain) was introduced into a polyoma virus expression vector and used to transfect murine NIH 3T3 cells. An EBV-associated nuclear antigen was detected in these cells in an indirect immunofluorescence test using anti-EBV nuclear antigen-positive human sera. These sera recognized a Mr 88,000 polypeptide in 3T3 cells transfected with the BamHI fragment K-containing polyoma virus plasmid by radioimmunoelectrophoresis. A Mr 88,000 polypeptide also was detected in a B-cell line latently infected with the B95-8 strain of EBV. Plasmids containing insertion and deletion mutations in BamHI fragment K directed the synthesis of truncated forms of the Mr 88,000 polypeptide in 3T3 cells. These data directly demonstrate that the polypeptide identified in EBV-infected lymphocyte lines by anti-EBV nuclear antigen-positive human sera is encoded by the viral genome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087322      PMCID: PMC345591          DOI: 10.1073/pnas.81.14.4373

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Epstein-Barr virus-specific RNA. III. Mapping of DNA encoding viral RNA in restringent infection.

Authors:  A L Powell; W King; E Kieff
Journal:  J Virol       Date:  1979-01       Impact factor: 5.103

2.  Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line.

Authors:  T Lindahl; A Adams; G Bjursell; G W Bornkamm; C Kaschka-Dierich; U Jehn
Journal:  J Mol Biol       Date:  1976-04-15       Impact factor: 5.469

3.  Epstein-barr virus-specific RNA. II. Analysis of polyadenylated viral RNA in restringent, abortive, and prooductive infections.

Authors:  T Orellana; E Kieff
Journal:  J Virol       Date:  1977-05       Impact factor: 5.103

4.  An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.

Authors:  G Klein; B Giovanella; A Westman; J S Stehlin; D Mumford
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

5.  EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx.

Authors:  H zur Hausen; H Schulte-Holthausen; G Klein; W Henle; G Henle; P Clifford; L Santesson
Journal:  Nature       Date:  1970-12-12       Impact factor: 49.962

6.  Cloning of immunoglobulin-producing human leukemic and lymphoma cells in long-term cultures.

Authors:  Y Hinuma; J T Grace
Journal:  Proc Soc Exp Biol Med       Date:  1967-01

7.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

8.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

9.  Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis.

Authors:  V Diehl; G Henle; W Henle; G Kohn
Journal:  J Virol       Date:  1968-07       Impact factor: 5.103

10.  Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas.

Authors:  G Klein; T Lindahl; M Jondal; W Leibold; J Menézes; K Nilsson; C Sundström
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

View more
  21 in total

1.  Interaction of Epstein-Barr virus nuclear antigen 1 with the viral latent origin of replication.

Authors:  J Hearing; Y Mülhaupt; S Harper
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  cDNA cloning and transient expression of the Epstein-Barr virus-determined nuclear antigen EBNA3B in human cells and identification of novel transcripts from its coding region.

Authors:  B Kerdiles; D Walls; H Triki; M Perricaudet; I Joab
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  Latent and viral replicative transcription in vivo from the BamHI K fragment of Epstein-Barr virus DNA.

Authors:  R Weigel; G Miller
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

4.  Deletion mutants that affect expression of Epstein-Barr virus nuclear antigen in COS-1 cells after gene transfer with simian virus 40 vectors containing portions of the BamHI K fragment.

Authors:  M Polvino-Bodnar; D Shedd; G Miller
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

5.  Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family.

Authors:  K Hennessy; F Wang; E W Bushman; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

6.  Epstein-Barr virus mRNAs produced by alternative splicing.

Authors:  M Bodescot; M Perricaudet
Journal:  Nucleic Acids Res       Date:  1986-09-11       Impact factor: 16.971

7.  Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site.

Authors:  J Sample; M Hummel; D Braun; M Birkenbach; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Mutational analysis of Epstein-Barr virus nuclear antigen 1 (EBNA 1).

Authors:  M Polvino-Bodnar; J Kiso; P A Schaffer
Journal:  Nucleic Acids Res       Date:  1988-04-25       Impact factor: 16.971

9.  Sequence requirements of the Epstein-Barr virus latent origin of DNA replication.

Authors:  S Harrison; K Fisenne; J Hearing
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Identification of cellular factors that bind specifically to the Epstein-Barr virus origin of DNA replication.

Authors:  S J Oh; T Chittenden; A J Levine
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.